Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy

Q: What does this research mean for the field?

Vamorolone treatment shows promise in improving muscle function in boys aged 7 to <18 years with Duchenne muscular dystrophy. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

The aim is to evaluate the effects of vamorolone on boys with Duchenne muscular dystrophy.

Hanns Lochmüller; H. Gonorazky; Elisa Nigro; Jean Kit-Wah Mah; A. Aleman; Amanda Yaworski; M. Saket Oskoui; Anne Marie Sbrocchi; Kathryn Selby; Ana de Vera; Laura McAdam; Ekaterina Gresko; A. Linden; Catherine Dutreix; E. Hoffman

doi:10.1007/s00415-026-13711-6

March 1, 2026Journal of NeurologyOpen Access

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the effects of vamorolone on boys with Duchenne muscular dystrophy.
Phase II clinical trial design
Open-label multiple-dose administration
Participants aged 7 to <18 years
Assessment of efficacy and safety
Evaluation of clinical outcomes related to muscular function
Safety profile of vamorolone administration
Improvement in specific muscular dystrophy symptoms observed

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Phase II trial demonstrates effects of vamorolone on Duchenne muscular dystrophy in boys, suggesting potential treatment benefits.

Abstract

ClinicalTrials.gov: NCT05185622, NCT03863119. First submitted 09-11-2021.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lochmüller et al. (2026) studied this question.

synapsesocial.com/papers/69a91d6dd6127c7a504c01f6 https://doi.org/10.1007/s00415-026-13711-6

View Full Paper

Ask AI

Bookmark

Share

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading